RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.
Antev Limited (Antev) is a clinical-stage biopharmaceutical company focused on the development of a drug for prostate cancer, Teverelix TFA.
CAUTION: This project has not been approved as a financial promotion. No investment decisions about the project should be made on the basis of information provided on this platform.
This company has not shared it's twitter feed.
Antev have developed a substantially differentiated product, teverelix TFA, a long-acting injectable gonadotrophin-releasing hormone (GnRH) antagonist with a novel microcrystal formulation, which is able to overcome the historical problems of previous GnRH antagonist candidates while also reducing injection site reactions.
Antev have acquired a strong intellectual property estate and are expanding its patent protection. The company is currently preparing phase IIb clinical programmes for prostate cancer.
As a pre-revenue company, Antev seeks to increase shareholder value by progressing the development of teverelix TFA towards registration. Approval is anticipated from 2023 onwards.
Investment Focus: Equity and Debt
About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.
Contact Name: Oliver Woolley
Registered InvestorsOver 1000
Investment through platformOver £100m